5,898 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Fermata Advisors LLC

Fermata Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,898 shares of the company's stock, valued at approximately $410,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after buying an additional 23,223 shares during the period. Bryn Mawr Capital Management LLC boosted its holdings in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares during the period. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 16.7% in the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after purchasing an additional 286,912 shares during the period. Channing Global Advisors LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $354,000. Finally, Compagnie Lombard Odier SCmA boosted its holdings in Novo Nordisk A/S by 5.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company's stock valued at $5,827,000 after purchasing an additional 3,200 shares during the period. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $72.57 on Friday. The firm has a 50 day moving average of $65.73 and a 200-day moving average of $80.90. The stock has a market capitalization of $325.64 billion, a PE ratio of 22.06, a PEG ratio of 0.90 and a beta of 0.66. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.